Insider · CIK 0001373097
William A Jones Jr
directorofficer
Files at ANNX (Annexon, Inc.), NAMS (NewAmsterdam Pharma Co N.V.), APGE (Apogee Therapeutics, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 3, 2026 | APGE Apogee Therapeutics, Inc. | DDisposition to issuer Common Stock | -34,824 | - | - | 0 | 39 d ago |
| Sep 3, 2026 | APGE Apogee Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -10,370 | - | - | 0 | 39 d ago |
| Sep 3, 2026 | APGE Apogee Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -14,461 | - | - | 0 | 39 d ago |
| Sep 3, 2026 | APGE Apogee Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -7,657 | - | - | 0 | 39 d ago |
| Jun 17, 2025 | APGE Apogee Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +14,461 | $0.00 | $0 | 14,461 | Jun 20, 2025 |
| Jun 5, 2025 | ANNX Annexon, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +55,000 | $0.00 | $0 | 55,000 | Jun 9, 2025 |
| Jan 9, 2025 | ANNX Annexon, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +88,000 | $0.00 | $0 | 88,000 | Jan 10, 2025 |
| Jan 7, 2025 | NAMS NewAmsterdam Pharma Co N.V. | AGrant or award Ordinary Shares | +43,000 | - | - | 43,000 | Jan 7, 2025 |
| Jan 2, 2025 | NAMS NewAmsterdam Pharma Co N.V. | AGrant or award Option (right to buy)derivative | +200,000 | $0.00 | $0 | 200,000 | Jan 6, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.